Genetic predisposition to statin myopathy
- 1 November 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 20 (6) , 648-655
Abstract
Genetic predisposition to statin myopathy is a rapidly expanding area of investigation. This review summarizes the latest information on genetic risk factors associated with statin-induced myopathy. Genetic determinants involved in both pharmacokinetics of statins and metabolic muscle diseases are discussed. Data are provided on the prevalence of statin use in the United States; incidence of associated myopathy; terminology relating to statin myopathy and genetic susceptibility; and common myths surrounding this disorder. Technological advances now make it possible to identify genetic variation in the human genome that reveals disease-causing mutations and single nucleotide polymorphisms associated with disease. More than 30,000 individuals in the United States suffer from severe life-threatening symptoms of statin-induced myopathy that may, in some cases, persist long after the cessation of therapy. Genes of interest include those involved in the pharmacokinetics of the statin response, muscle atrophy, exercise intolerance, pain perception, and mitochondrial energy metabolism. Genetic analysis for variants and disease-causing mutations relevant to statin myopathy will provide predisposition testing for this and other drug-induced disorders. This testing will become an integral part of personalized medicine that will contribute to the safe and informed use of selected drugs and improved compliance.Keywords
This publication has 47 references indexed in Scilit:
- Functional characterization of human COQ4, a gene required for Coenzyme Q10 biosynthesisBiochemical and Biophysical Research Communications, 2008
- ADCK3, an Ancestral Kinase, Is Mutated in a Form of Recessive Ataxia Associated with Coenzyme Q10 DeficiencyThe American Journal of Human Genetics, 2008
- CYP2D6*4 polymorphism is associated with statin-induced muscle effectsPharmacogenetics and Genomics, 2007
- The Role of Coenzyme Q10 in Statin-Associated MyopathyJACC, 2007
- Genetic determinants of statin intoleranceLipids in Health and Disease, 2007
- Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disordersJournal of Clinical Investigation, 2007
- Mutations in coenzyme Q10 biosynthetic genesJournal of Clinical Investigation, 2007
- Leigh Syndrome with Nephropathy and CoQ10 Deficiency Due to decaprenyl diphosphate synthase subunit 2 (PDSS2) MutationsThe American Journal of Human Genetics, 2006
- Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national surveyAmerican Heart Journal, 2006
- Familial idiopathic hyper‐CK‐emia: An underrecognized conditionMuscle & Nerve, 2006